Friday, 16 October 2026European Markets

ORKLA, OENEO, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - orkla (ork.ol) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
orkla (ork.ol) kr74.46 4.08% 12.77%
oeneo (sbt.pa) €14.40 2.07% 12.71%
lotus bakeries (lotb.br) €6140.00 0.65% 18.92%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. orkla (ork.ol)

4.08% forward dividend yield and 12.77% return on equity

orkla asa engages in branded consumer goods, and industrial and financial investment businesses. the company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery channels, as well as food service, convenience stores, and petrol stations. it also provides confectionery, biscuit, and snack products; and develops bran and crispbread products, as well as energy snack meals. in addition, the company offers personal care and cleaning products; dietary supplement, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools; basic and wool garments for men, women, and children; and professional cleaning products. further, it operates gymgrossisten, proteinfabrikken, bodystore, and fitnessmarket e-commerce portals for health and sports nutrition products; and restaurants. additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the nordic power market; and develops and sells real estate properties. it offers its food products under the grandiosa, toro, stabburet, felix, paulúns, naturli', abba, beauvais, den gamle fabrik, spilva, and vitana brands; confectionery and snacks under the kims, nidar, stratos, sætre, göteborgs kex, olw, panda, laima, selga, taffel, kalev, and nói síríus brands; health and sports nutrition under e zalo, jif, bliw, grumme, blenda, define, möller's, collett, nutrilett, maxim, norgesplaster, and salvequick brands; and food ingredients under the odense, mors hjemmebakte, kronjäst, bakkedal, and naturli brands. it has operations in norway, sweden, denmark, finland, iceland, the baltics, rest of europe, and internationally. the company was founded in 1918 and is headquartered in oslo, norway.

earnings per share

as for profitability, orkla has a trailing twelve months eps of kr4.37.

pe ratio

orkla has a trailing twelve months price to earnings ratio of 17.04. meaning, the purchaser of the share is investing kr17.04 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.77%.

more news about orkla.

2. oeneo (sbt.pa)

2.07% forward dividend yield and 12.71% return on equity

oeneo sa operates in the wine industry worldwide. the company manufactures and sale of cork closures. it also provides solutions in wine making and spirits. oeneo sa is headquartered in bordeaux, france. oeneo sa is a subsidiary of caspar sas.

earnings per share

as for profitability, oeneo has a trailing twelve months eps of €0.63.

pe ratio

oeneo has a trailing twelve months price to earnings ratio of 22.86. meaning, the purchaser of the share is investing €22.86 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.71%.

revenue growth

year-on-year quarterly revenue growth grew by 9.2%, now sitting on 340.62m for the twelve trailing months.

more news about oeneo.

3. lotus bakeries (lotb.br)

0.65% forward dividend yield and 18.92% return on equity

lotus bakeries nv provides various snack products in belgium and internationally. the company offers biscuits and cakes, including caramelized cookies, gingerbreads, cake specialties, waffles, and pepparkakor biscuits. it also provides energy bars, protein flapjacks, protein nut bars, healthy snacks, butter specialties, ice creams, and caramelized cookies spreads. the company sells its products under the lotus biscoff, nakd, trek, bear, kiddylicious, lotus, dinosaurus, peijnenburg, snelle jelle, annas, lotus suzy, and urban fruit brands. the company was founded in 1932 and is headquartered in lembeke, belgium. lotus bakeries nv is a subsidiary of stichting administratiekantoor van aandelen lotus bakeries.

earnings per share

as for profitability, lotus bakeries has a trailing twelve months eps of €101.82.

pe ratio

lotus bakeries has a trailing twelve months price to earnings ratio of 60.3. meaning, the purchaser of the share is investing €60.3 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.92%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, lotus bakeries's stock is considered to be oversold (<=20).

more news about lotus bakeries.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com